Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Exp Eye Res. 2019 Sep 11;188:107798. doi: 10.1016/j.exer.2019.107798

Figure 5. PEDF 335 delivery via eye drops was effective in attenuation of CNV.

Figure 5.

Animals (5 per group) received vehical alone or PEDF 335 peptide by one-time IVT injection (1 μL of 4 mM peptide). The topical treatment groups (10 mice / group received 10 mM peptide or saline (5 μL drop, bid, Mon-Fri) starting at day −7. (A) shows the schedule of eye drop or IVT dosing and eye harvest and fixation. Animals were then treated with laser on day 0 and topical delivery of the peptide or saline control drops continued Mon-Fri during the ensuing 14 day period. Animals were then sacrificed and RPE/Choroid flatmounts were stained with ICAM-2 antibody and was determined as described in Methods. (B) Area of vascularization for IVT injection at day −3. (C) Area of vascularization for topical treatment. Inhibition was similarly significant for both treatments, (*P< 0.05).